Welcome to our dedicated page for Barinthus Biotherapeutics plc news (Ticker: BRNS), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics plc stock.
Barinthus Biotherapeutics plc (NASDAQ: BRNS), also known as Barinthus Bio, generates news primarily around its work in immunology and inflammation and its clinical-stage pipeline. The company focuses on developing novel immunotherapeutic candidates that promote antigen-specific immune tolerance for autoimmune and inflammatory diseases, with its lead program VTP-1000 in celiac disease.
News coverage for Barinthus Bio often highlights clinical trial progress, especially updates from the Phase 1 AVALON trial of VTP-1000 in adults with celiac disease. The company has reported that VTP-1000, an investigational antigen-specific tolerance immunotherapy using its SNAP-TI platform, was well tolerated in the single ascending dose portion of the trial with no treatment-related serious adverse events and dose-dependent pharmacological effects, and that the multiple ascending dose portion with a gluten challenge is ongoing.
Investors and followers of BRNS can also expect news on pipeline and strategic developments, including Barinthus Bio’s strategic refocus on immunology and inflammation, its partnering efforts for viral vector-based programs such as VTP-300 in chronic hepatitis B and VTP-850 in prostate cancer, and financial updates describing its cash runway and restructuring activities. Press releases have detailed data from Phase 2 trials of VTP-300 in chronic hepatitis B and the status of other clinical programs.
Another key source of news is the proposed combination with Clywedog Therapeutics, Inc., a private company focused on metabolic and autoimmune diseases. Announcements describe a definitive merger agreement to form a combined company, Clywedog Therapeutics, Inc., expected to trade on Nasdaq under the ticker CLYD upon closing, with a portfolio including clinical-stage candidates in Type 1 diabetes, Type 2 diabetes, and celiac disease. Readers of the BRNS news page can follow updates on this transaction, related SEC filings, and corporate presentations at investor conferences.
By monitoring the Barinthus Bio news feed, users can track clinical milestones, corporate strategy, financial disclosures, and transaction-related developments that shape the company’s evolution in the immunology and inflammation space.
Barinthus Biotherapeutics (NASDAQ: BRNS) will present clinical data for its hepatitis B immunotherapy candidate, VTP-300, at the EASL Congress 2024 in Milan, Italy, from June 5-8. The presentations will include a poster on June 5 and an oral presentation on June 6. The poster will discuss how VTP-300 combined with nivolumab continues to show reductions in HBsAg levels without serious adverse events. The oral presentation will highlight that VTP-300, when administered after imdusiran, maintains lower HBV surface antigen levels and allows more subjects to discontinue NUC therapy. CEO Bill Enright expressed optimism about the potential for a functional cure for hepatitis B.
Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported its first quarter 2024 financial results highlighting progress in its T cell immunotherapy programs. The Company received FDA clearance for a Phase 1 trial in celiac disease and reported positive data from a HPV study. Barinthus also announced the appointment of a new Chief Medical Officer and upcoming milestones for 2024. Financially, the Company's cash position decreased, with no revenue in Q1 2024. Despite increased R&D expenses, the net loss decreased compared to Q1 2023.
Barinthus Biotherapeutics plc announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer. Dr. Hooftman brings over 25 years of experience in international drug development, specializing in immunology, autoimmunity, hematology, oncology, and infectious diseases. His extensive background includes successful clinical trial programs and senior management positions at leading pharmaceutical companies. Dr. Hooftman's appointment is expected to drive the development of Barinthus Bio's novel T cell immunotherapeutic candidates for chronic infectious diseases, autoimmunity, and cancer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.